Recent advances in obesity pharmacotherapy.Curr Clin Pharmacol. 2009 Jan; 4(1):53-61.CC
Abstract
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
19149502
Citation
Mayer, Marcos A., et al. "Recent Advances in Obesity Pharmacotherapy." Current Clinical Pharmacology, vol. 4, no. 1, 2009, pp. 53-61.
Mayer MA, Höcht C, Puyó A, et al. Recent advances in obesity pharmacotherapy. Curr Clin Pharmacol. 2009;4(1):53-61.
Mayer, M. A., Höcht, C., Puyó, A., & Taira, C. A. (2009). Recent advances in obesity pharmacotherapy. Current Clinical Pharmacology, 4(1), 53-61.
Mayer MA, et al. Recent Advances in Obesity Pharmacotherapy. Curr Clin Pharmacol. 2009;4(1):53-61. PubMed PMID: 19149502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Recent advances in obesity pharmacotherapy.
AU - Mayer,Marcos A,
AU - Höcht,Christian,
AU - Puyó,Ana,
AU - Taira,Carlos A,
PY - 2009/1/20/entrez
PY - 2009/1/20/pubmed
PY - 2009/5/19/medline
SP - 53
EP - 61
JF - Current clinical pharmacology
JO - Curr Clin Pharmacol
VL - 4
IS - 1
N2 - Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
SN - 1574-8847
UR - https://www.unboundmedicine.com/medline/citation/19149502/Recent_advances_in_obesity_pharmacotherapy_
L2 - https://www.ingentaconnect.com/openurl?genre=article&issn=1574-8847&volume=4&issue=1&spage=53&aulast=Mayer
DB - PRIME
DP - Unbound Medicine
ER -